2024 Volume 80 Issue 3.4 Pages 107-112
【Introduction】
Salt restriction is important for the treatment of hypertension and there is evidence that reducing salt intake to less than 6 g/day has an effective antihypertensive effect and is expected to reduce cardiovascular events and cardiovascular death. However, many diabetic patients with hypertension fail to decrease their salt intake sufficiently in clinical practice.
【Objective】
To effectively restrict salt intake in individuals with type 2 diabetes （T2D）, the aim of this study was to clarify the clinical factors that influence estimated salt intake （eSI）.
【Methods】
We continuously enrolled 268 individuals with T2D and assessed their eSI using Tanakaʼs formula through spot urine analysis at Anan Medical Center, Tokushima Japan. The relationships between eSI and the clinical factors were statistically evaluated.
【Results】
Multivariate analysis including clinical factors and medications used for the determinants of eSI showed positive associations of BMI and duration of diabetes with eSI and showed a negative association of serum uric acid and taking α-glucosidase inhibitor （α-GI） with eSI.
【Discussion】
It is possible that α-GI reduces sodium absorption from the intestine, which leads to decreased urinary sodium excretion, given the fact that α-GI inhibits sodium and glucose absorption from the intestine. In addition, since the urate transporter-1 promotes reabsorption of uric acid and sodium in the renal tubules, reduced urinary excretion of uric acid may be associated with reduced urinary sodium excretion.
【Conclusion】
In addition to diet and exercise therapy, there is a possibility that oral administration of α-GI contributes to salt reduction in individuals with T2D.
